Please login to the form below

Not currently logged in
Email:
Password:

heart failure drug

This page shows the latest heart failure drug news and features for those working in and with pharma, biotech and healthcare.

Novartis hit by ‘COVID-19-related lockdowns’ in Q4

Novartis hit by ‘COVID-19-related lockdowns’ in Q4

added. In the Q4 results, Novartis highlighted its main growth drivers – including its heart failure drug Entresto (sacubitril/valsartan), its immunology therapy Cosentyx (secukinumab) and its spinal muscular atrophy (SMA) gene

Latest news

More from news
Approximately 0 fully matching, plus 76 partially matching documents found.

Latest Intelligence

  • Integrating patient reported outcomes into clinical trials Integrating patient reported outcomes into clinical trials

    Drug developers have responded by putting PROs at the heart of their clinical trial designs. ... The performance of Novartis’ heart failure drug Entresto offers one example of that potential.

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Ivabradine is thought to be the first drug to work by decreasing the heart rate as a consequence of its action on the If channel that controls the intrinsic pacemaker in ... In the 6, 500-patient SHIFT trial, for example, the drug showed a significant

  • Pharma deals during July 2013 Pharma deals during July 2013

    Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates. ... Omecamtiv mecarbil is currently in phase II trials

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....